Sherbrooke Park Advisers LLC Purchases 3,162 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Sherbrooke Park Advisers LLC lifted its position in 10x Genomics, Inc. (NASDAQ:TXG) by 10.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 33,311 shares of the company’s stock after buying an additional 3,162 shares during the period. Sherbrooke Park Advisers LLC’s holdings in 10x Genomics were worth $478,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in TXG. Entropy Technologies LP lifted its position in 10x Genomics by 285.6% during the fourth quarter. Entropy Technologies LP now owns 37,595 shares of the company’s stock valued at $540,000 after purchasing an additional 27,844 shares during the period. SG Americas Securities LLC lifted its position in 10x Genomics by 209.8% during the fourth quarter. SG Americas Securities LLC now owns 73,046 shares of the company’s stock valued at $1,049,000 after purchasing an additional 49,468 shares during the period. Alberta Investment Management Corp bought a new position in 10x Genomics during the fourth quarter valued at approximately $3,206,000. China Universal Asset Management Co. Ltd. bought a new position in 10x Genomics during the fourth quarter valued at approximately $326,000. Finally, Barclays PLC lifted its position in 10x Genomics by 11.7% during the third quarter. Barclays PLC now owns 602,536 shares of the company’s stock valued at $13,605,000 after purchasing an additional 63,079 shares during the period. Institutional investors own 84.68% of the company’s stock.

Insider Activity at 10x Genomics

In related news, Director Alan Mateo bought 40,000 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was bought at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the purchase, the director now owns 61,691 shares of the company’s stock, valued at approximately $687,237.74. The trade was a 184.41% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 5,092 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the transaction, the chief executive officer now directly owns 879,482 shares of the company’s stock, valued at $9,735,865.74. The trade was a 0.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.39% of the stock is currently owned by corporate insiders.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $9.39 on Friday. The firm has a fifty day moving average price of $8.77 and a 200-day moving average price of $12.33. The stock has a market cap of $1.15 billion, a PE ratio of -6.18 and a beta of 1.94. 10x Genomics, Inc. has a 1 year low of $6.78 and a 1 year high of $25.55.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. The firm had revenue of $154.88 million during the quarter, compared to analysts’ expectations of $131.91 million. 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.50) earnings per share. On average, research analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on TXG shares. Canaccord Genuity Group lowered their price objective on shares of 10x Genomics from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, May 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, May 10th. The Goldman Sachs Group reduced their target price on shares of 10x Genomics from $7.50 to $6.50 and set a “sell” rating for the company in a report on Monday, May 12th. Barclays reduced their target price on shares of 10x Genomics from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Finally, Leerink Partnrs cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $16.42.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.